Current trends in the management of graves’ disease

Journal of Clinical Endocrinology and Metabolism

Volumn 70, Issue 6, 1990, Pages 1518-1524

  Solomon, Barbara ^a,b   Glinoer, Daniel ^b,c   Lagasse, Raphael ^b,c   Wartofsky, Leonard ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RADIOISOTOPE; THIAMAZOLE; THYROTROPIN; THYROXINE;

ARTICLE; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; SURGERY; THYROID FUNCTION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANTITHYROID AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GRAVES' DISEASE; HUMAN; IODINE RADIOISOTOPES; MALE; PROPYLTHIOURACIL; QUESTIONNAIRES;

EID: 0025303427     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem-70-6-1518     Document Type: Article

References (12)

1. Burman KD. Hyperthyroidism. In: Becker KL, ed. Principles and practice of endocrinology, 1st ed. Philadelphia: Lippincott; 1990;331-47.
2. Burman KD, Baker Jr JR. Immune mechanisms in Graves’ disease. Endocr Rev. 1985;6:183-232.
3. Ridgway EC. Thyrotropin radioimmunoassays: birth, life, and demise. Mayo Clin Proc. 1988;63:1028-34.
4. Wartofsky L. Low remission after therapy for Graves’ disease: possible relation of dietary iodine with antithyroid therapy results. JAMA. 1973;226:1083-8.
5. Solomon BL, Evaul JE, Burman KD. Wartofsky L. Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med. 1987;107:510-2.
6. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves’ Disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh). 1987; 185(Suppl):9-37.
7. Nie NH, Hull CM, Jenkins JG, Steinbrenner K, Benta DM. Statistical package for the social sciences, 2nd ed. New York: McGrawHill; 1975.
8. Greer MA, Kammer H, Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N Engl J Med. 1977;297:173-6.
9. Bouma DJ, Kammer H, Greer MA. Follow-up comparison of shortterm versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. J Clin Endocrinol Metab. 1982;55:1138-42.
10. Toft AD. Use of sensitive immunoradiometric assay for thyrotropin in clinical practice. Mayo Clin Proc. 1988;63:1035-42.
11. 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy. Acta Endocrinol (Copenh) 1981;98:364-9.
12. Dunn JT. Choice of therapy in young adults with hyperthyroidism of Graves’ disease—a brief, case-directed poll of fifty-four thyroi-dologists. Ann Intern Med. 1984;100:891-3.